Cargando…

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

INTRODUCTION: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype have not been systematically described. METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choudhury, Noura J., Schneider, Jaime L., Patil, Tejas, Zhu, Viola W., Goldman, Debra A., Yang, Soo-Ryum, Falcon, Christina J., Do, Andrew, Nie, Yunan, Plodkowski, Andrew J., Chaft, Jamie E., Digumarthy, Subba R., Rekhtman, Natasha, Arcila, Maria E., Iasonos, Alexia, Ou, Sai-Hong I., Lin, Jessica J., Drilon, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474494/ https://www.ncbi.nlm.nih.gov/pubmed/34590036 http://dx.doi.org/10.1016/j.jtocrr.2021.100187

Ejemplares similares

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2016)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology
por: Patil, Tejas, et al.
Publicado: (2022)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements
por: Digumarthy, Subba R., et al.
Publicado: (2020)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

CT features of HER2-mutant lung adenocarcinomas
por: Sawan, Peter, et al.
Publicado: (2018)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance
por: Sakamoto, Mandy, et al.
Publicado: (2023)

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
por: Desilets, Antoine, et al.
Publicado: (2023)

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer
por: Suzawa, Ken, et al.
Publicado: (2019)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
por: Lim, Sun Min, et al.
Publicado: (2017)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large cell carcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2012)

Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate
por: Arcila, Maria E., et al.
Publicado: (2020)

Mouse Model for ROS1-Rearranged Lung Cancer
por: Arai, Yasuhito, et al.
Publicado: (2013)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme
por: Lim, Sun Min, et al.
Publicado: (2015)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
por: Ikushima, Hiroaki, et al.
Publicado: (2021)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies
por: Iasonos, Alexia, et al.
Publicado: (2008)

MRI in detection of hepatocellular carcinoma (HCC)
por: Digumarthy, Subba R, et al.
Publicado: (2005)

A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups
por: Satagopan, Jaya M., et al.
Publicado: (2017)

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer
por: Schram, Alison M., et al.
Publicado: (2016)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition
por: von Reibnitz, Donata, et al.
Publicado: (2018)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK ‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
por: Ng, Terry L., et al.
Publicado: (2022)

Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell
por: Zhao, Jing, et al.
Publicado: (2016)

A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis
por: Takahara, Yutaka, et al.
Publicado: (2020)

Use of radiomics to differentiate left atrial appendage thrombi and mixing artifacts on single-phase CT angiography
por: Ebrahimian, Shadi, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy
por: Ma, Rui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8n3oruh4hjn1k6agq5f47q5f5s